Stocktoria
OCULAR THERAPEUTIX, INC OCUL
OCULAR THERAPEUTIX, INC (OCUL) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $52.0M at a -511.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.85 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-25 | Chardan Capital | Buy (main) |
| 2026-06-18 | HC Wainwright & Co. | Buy (reit) |
| 2026-06-18 | Baird | Outperform (main) |
| 2026-05-06 | RBC Capital | Outperform (reit) |
| 2026-05-05 | Needham | Buy (reit) |
| 2026-04-13 | HC Wainwright & Co. | Buy (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.905 |
| Retained earnings / assets | -1.432 |
| EBIT / assets | -0.334 |
| Equity / liabilities | 4.256 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OCUL | OCULAR THERAPEUTIX, INC | 3/9 | 3.49 | — | -18.5% |
| XOMA | XOMA Royalty Corp | 5/9 | -11.82 | 23.3 | +83.1% |
| QTTB | Q32 Bio Inc. | 3/9 | -2.11 | 7.5 | — |
| AGIO | AGIOS PHARMACEUTICALS, INC. | 2/9 | 12.52 | — | +48% |
| LXRX | LEXICON PHARMACEUTICALS, INC. | 3/9 | — | — | +60.2% |
| NKTR | NEKTAR THERAPEUTICS | 1/9 | — | — | -43.9% |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
About OCULAR THERAPEUTIX, INC
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
FAQ
Is OCUL financially healthy?
OCULAR THERAPEUTIX, INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does OCUL pay a dividend?
No, OCULAR THERAPEUTIX, INC does not currently pay a dividend.
How profitable is OCUL?
In FY2025, OCULAR THERAPEUTIX, INC had a net margin of -511.9% and a return on equity of -40.6%.
What is the analyst price target for OCUL?
The average Wall-Street price target for OCULAR THERAPEUTIX, INC is $27.09, about 164.8% above the recent price, from 11 analysts (consensus: strong buy).
Is OCUL a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on OCULAR THERAPEUTIX, INC: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.